Cargando…
Occurrence of Psoriatic Arthritis during Interferon Beta 1a Treatment for Multiple Sclerosis
Interferon beta (IFN-β) is the first line therapy of relapsing-remitting multiple sclerosis. IFN-β is a cytokine that can contribute to the development of systemic autoimmune disease including psoriasis. The development or the exacerbation of psoriasis during IFN-β treatment has been previously obse...
Autores principales: | Toussirot, Éric, Béreau, Matthieu, Bossert, Marie, Malkoun, Imad, Lohse, Anne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009278/ https://www.ncbi.nlm.nih.gov/pubmed/24839574 http://dx.doi.org/10.1155/2014/949317 |
Ejemplares similares
-
Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010) -
Ustekinumab in chronic immune-mediated diseases: a review of long term safety and patient improvement
por: Toussirot, Éric, et al.
Publicado: (2013) -
Could Sodium Chloride be an Environmental Trigger for Immune-Mediated Diseases? An Overview of the Experimental and Clinical Evidence
por: Toussirot, Eric, et al.
Publicado: (2018) -
The cardiometabolic conditions of psoriatic disease
por: Toussirot, Eric, et al.
Publicado: (2022) -
Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
por: Bachelet, Delphine, et al.
Publicado: (2016)